source
- BMS lung drug meets low-dose endpoint in Phase 3 but high dose fails to improve lung functionBristol Myers Squibb reported that its LPA1 antagonist admilparant achieved the primary endpoint in a Phase 3 idiopathic pulmonary fibrosis study at the 60‑mg dose, showing a statistically signific…
- RevMed's pancreatic cancer drug Rasonque shows mixed results across KRAS subtypes, analysts stay optimisticFDA review documents revealed that Revolution Medicines' newly approved pancreatic cancer therapy, Rasonque, performed unevenly in a large subgroup of patients. The data highlight a lower objective…